

Haran Yogasundaram

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8472367/publications.pdf>

Version: 2024-02-01

27
papers

743
citations

759233

12
h-index

580821

25
g-index

27
all docs

27
docs citations

27
times ranked

1433
citing authors

#	ARTICLE	IF	CITATIONS
1	Burden of Valvular Heart Disease in Patients with Fabry Disease. <i>Journal of the American Society of Echocardiography</i> , 2022, 35, 236-238.	2.8	3
2	Outcomes of pregnancy in women with hypertrophic cardiomyopathy: A systematic review. <i>International Journal of Cardiology</i> , 2022, 359, 54-60.	1.7	7
3	Nationwide study of sex differences in incident heart failure in newly diagnosed nonvalvular atrial fibrillation. <i>CJC Open</i> , 2022, , .	1.5	0
4	Plasma Exchange for Immune Checkpoint Inhibitor-Induced Myocarditis. <i>CJC Open</i> , 2021, 3, 379-382.	1.5	21
5	Cardiomyopathies and Genetic Testing in Heart Failure: Role in Defining Phenotype-Targeted Approaches and Management. <i>Canadian Journal of Cardiology</i> , 2021, 37, 547-559.	1.7	23
6	Slow bidirectional ventricular tachycardia as a manifestation of immune checkpoint inhibitor myocarditis. <i>European Heart Journal</i> , 2021, 42, 2868-2868.	2.2	6
7	Sex and Medium-term Outcomes of ST-Segment Elevation Myocardial Infarction in Kerala, India: Propensity Score-Matched Analysis. <i>CJC Open</i> , 2021, 3, S71-S80.	1.5	2
8	Battle of the Sexes: Differential Prognosis by Sex in Dilated Cardiomyopathy. <i>Canadian Journal of Cardiology</i> , 2020, 36, 7-10.	1.7	5
9	Cardiogenic Shock With Takotsubo Syndrome vs Myocardial Infarction: Better Short-term Outcomes but Significant Long-term Risk and Need for Surveillance. <i>Canadian Journal of Cardiology</i> , 2020, 36, 802-804.	1.7	1
10	Cardiorenal Syndrome and Heart Failure—Challenges and Opportunities. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1208-1219.	1.7	40
11	Comparison of Usefulness of Cardiac Resynchronization Therapy in Patients With Type 1 Myotonic Dystrophy With Versus Without Left Bundle Branch Block. <i>American Journal of Cardiology</i> , 2019, 124, 1770-1774.	1.6	11
12	Chloroquine-Induced cardiomyopathy: a reversible cause of heart failure. <i>ESC Heart Failure</i> , 2018, 5, 372-375.	3.1	41
13	Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2018, 7, e009098.	3.7	52
14	Novel Dominant-Negative Mutation in Cardiac Troponin I Causes Severe Restrictive Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	9
15	Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 805-819.	2.8	160
16	Clinical Features, Diagnosis, and Management of Patients With Anderson-Fabry Cardiomyopathy. <i>Canadian Journal of Cardiology</i> , 2017, 33, 883-897.	1.7	34
17	Reply to Letter From Floras et al.—Central Sleep Apnea: Risk Factor or Pathogenic Process in Patients With Heart Failure. <i>Canadian Journal of Cardiology</i> , 2016, 32, 396.e5.	1.7	0
18	Glycogen Storage Disease Because of a PRKAG2 Mutation Causing Severe Biventricular Hypertrophy and High-Grade Atrio-Ventricular Block. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	12

#	ARTICLE	IF	CITATIONS
19	MELAS syndrome and cardiomyopathy: linking mitochondrial function to heart failure pathogenesis. <i>Heart Failure Reviews</i> , 2016, 21, 103-116.	3.9	50
20	Increased Mortality Associated With Adaptive Servo-Ventilation Therapy in Heart Failure Patients With Central Sleep Apnea in the Halted SERVE-HF Trial. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1202-1203.	1.7	6
21	Gender-specific plasma proteomic biomarkers in patients with Anderson-Fabry disease. <i>European Journal of Heart Failure</i> , 2015, 17, 291-300.	7.1	38
22	Normal left-atrial structure and function despite concentric left-ventricular remodelling in a cohort of patients with Anderson-Fabry disease. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 1129-1136.	1.2	9
23	Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment. <i>Heart Failure Reviews</i> , 2015, 20, 179-191.	3.9	58
24	Hydroxychloroquine-Induced Cardiomyopathy: Case Report, Pathophysiology, Diagnosis, and Treatment. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1706-1715.	1.7	126
25	Cardiovascular Pathophysiology: Is It a Tumour Necrosis Factor Superfamily Affair?. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1492-1495.	1.7	2
26	The Harbinger of Mortality in Heart Failure With Preserved Ejection Fraction: Do GDF-15 Levels Reflect Tandem, Deterministic Effects of Fibrosis and Inflammation?. <i>Canadian Journal of Cardiology</i> , 2014, 30, 264-266.	1.7	5
27	BSA Nanoparticles for siRNA Delivery: Coating Effects on Nanoparticle Properties, Plasma Protein Adsorption, and <i>In Vitro</i> siRNA Delivery. <i>International Journal of Biomaterials</i> , 2012, 2012, 1-10.	2.4	22